LUPKYNIS

Aurinia Pharmaceuticals Inc. · FDA-approved active Small molecule

LUPKYNIS is a Calcineurin inhibitor Small molecule drug developed by Aurinia Pharmaceuticals Inc.. It is currently FDA-approved for Lupus nephritis (Class III or IV). Also known as: voclosporin.

LUPKYNIS (voclosporin) is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce lupus nephritis inflammation.

LUPKYNIS (voclosporin) is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce lupus nephritis inflammation. Used for Lupus nephritis (Class III or IV).

At a glance

Generic name	LUPKYNIS
Also known as	voclosporin
Sponsor	Aurinia Pharmaceuticals Inc.
Drug class	Calcineurin inhibitor
Target	Calcineurin (via cyclophilin binding)
Modality	Small molecule
Therapeutic area	Immunology / Nephrology
Phase	FDA-approved

Mechanism of action

Voclosporin binds to cyclophilin and inhibits calcineurin, a phosphatase required for T-cell receptor signaling and IL-2 transcription. This suppresses the proliferation and activation of T lymphocytes, reducing the autoimmune response in lupus nephritis. By decreasing pathogenic T-cell activity, it reduces proteinuria and preserves kidney function in patients with lupus-induced kidney disease.

Approved indications

• Lupus nephritis (Class III or IV)

Common side effects

• Hypertension
• Hyperkalemia
• Increased serum creatinine
• Headache
• Diarrhea
• Tremor
• Gum hyperplasia

Key clinical trials

• LUPKYNIS Drug-use Results Survey
• Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus (PHASE2)
• A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• LUPKYNIS CI brief — competitive landscape report
• LUPKYNIS updates RSS · CI watch RSS
• Aurinia Pharmaceuticals Inc. portfolio CI

Frequently asked questions about LUPKYNIS

What is LUPKYNIS?

LUPKYNIS is a Calcineurin inhibitor drug developed by Aurinia Pharmaceuticals Inc., indicated for Lupus nephritis (Class III or IV).

How does LUPKYNIS work?

LUPKYNIS (voclosporin) is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce lupus nephritis inflammation.

What is LUPKYNIS used for?

LUPKYNIS is indicated for Lupus nephritis (Class III or IV).

Who makes LUPKYNIS?

LUPKYNIS is developed and marketed by Aurinia Pharmaceuticals Inc. (see full Aurinia Pharmaceuticals Inc. pipeline at /company/aurinia-pharmaceuticals-inc).

Is LUPKYNIS also known as anything else?

LUPKYNIS is also known as voclosporin.

What drug class is LUPKYNIS in?

LUPKYNIS belongs to the Calcineurin inhibitor class. See all Calcineurin inhibitor drugs at /class/calcineurin-inhibitor.

What development phase is LUPKYNIS in?

LUPKYNIS is FDA-approved (marketed).

What are the side effects of LUPKYNIS?

Common side effects of LUPKYNIS include Hypertension, Hyperkalemia, Increased serum creatinine, Headache, Diarrhea, Tremor.

What does LUPKYNIS target?

LUPKYNIS targets Calcineurin (via cyclophilin binding) and is a Calcineurin inhibitor.

Related

• Drug class: All Calcineurin inhibitor drugs
• Target: All drugs targeting Calcineurin (via cyclophilin binding)
• Manufacturer: Aurinia Pharmaceuticals Inc. — full pipeline
• Therapeutic area: All drugs in Immunology / Nephrology
• Indication: Drugs for Lupus nephritis (Class III or IV)
• Also known as: voclosporin